Suggestions
Greg Panico
Senior Director at Johnson & Johnson
Professional Background
Greg Panico is a distinguished professional in the pharmaceutical industry, leveraging his extensive knowledge in communications and leadership to shape the narrative around health and therapeutic areas. Currently serving as the Therapeutic Area Communications Leader at Janssen, one of the pharmaceutical companies that fall under the substantial umbrella of Johnson & Johnson, Greg plays a pivotal role in managing and directing communications strategies that aim to engage diverse stakeholders, including healthcare professionals, patients, and the general public. His adept coordination of complex projects underscores his capability to lead high-performing teams effectively.
Before stepping into his current role, Greg exhibited exceptional leadership as a Senior Director at Johnson & Johnson. In this capacity, he honed vital skills and gained extensive experience that have proven essential in his present endeavors. His tenure involved multiple projects where he was integral to aligning clinical developments with engaging communication strategies. This not only increased awareness but also drove meaningful conversations around crucial therapeutic innovations.
Greg’s public relations expertise is marked by his strategic vision and ability to articulate key scientific data into impactful messages that resonate with varied audiences. His commitment to transparency in communication continually contributes to enhancing dialogues between healthcare providers and patients, ultimately empowering them to make informed health decisions.
Education and Achievements
Greg Panico attended Fordham University, where he pursued a Bachelor of Arts degree in Communications. This foundational education equipped him with the essential skills in strategic communication, public relations, and interpersonal communication, laying the groundwork for a thriving career in the health and pharmaceutical sectors. Through his studies, Greg cultivated a keen understanding of how effective communication shapes perceptions and influences actions in the healthcare landscape.
Greg’s academic pursuits were characterized by a commitment to integrating practical experiences with theoretical learning. Fordham University’s robust program offered him opportunities for hands-on experiences, which he capitalized on, effectively blending his academic background with real-world applications in healthcare communications.
Throughout his career, Greg has continuously demonstrated a commitment to professional development, thereby consistently enhancing his contributions to the field. His strategic mindset has allowed him to navigate the challenges of pharmaceutical communications with agility and foresight.
Achievements
Among his notable achievements, Greg has successfully led numerous high-impact communications initiatives that have amplified the visibility and understanding of Janssen's therapeutic advances. He has been recognized for his skill in simplifying complex medical information, making it accessible and understandable for various audience segments—essential in fostering trust and engagement in healthcare.
His contributions to the field extend beyond his immediate role; Greg has become a key figure in advocating for effective health communication practices that promote patient education and involvement. He has participated in several conferences and workshops that focus on the importance of clear communication in the medical field, further solidifying his reputation as a thought leader.
In summary, Greg Panico is a dedicated communications leader in the pharmaceutical industry, with a wealth of experience and a profound understanding of the dynamics of healthcare communication. His background in communications from Fordham University, coupled with his leadership roles at Johnson & Johnson and Janssen, highlights his capacity to lead and innovate in a complex and rapidly evolving field. Driven by a passion for improving health communication, Greg continues to make significant strides in enhancing public understanding and engagement in therapeutic advancements.
